Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 13Leukemia, Myeloid, Acute 12Neoplasm Metastasis 11Lymphoma 11Pancreatic Neoplasms 9Burkitt Lymphoma 8Breast Neoplasms 8Myelodysplastic Syndromes 7Glioma 7Leukemia, Lymphocytic, Chronic, B-Cell 6Colorectal Neoplasms 6Triple Negative Breast Neoplasms 5Sarcoma 5Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neuroblastoma 5Lymphoma, Non-Hodgkin 5Central Nervous System Neoplasms 5Carcinoma, Renal Cell 5Wilms Tumor 4Squamous Cell Carcinoma of Head and Neck 4Rhabdoid Tumor 4Ovarian Neoplasms 4Oropharyngeal Neoplasms 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Lymphoma, T-Cell 4Lung Neoplasms 4Histiocytosis, Langerhans-Cell 4Hepatoblastoma 4

Interventions

relugolix 1enzalutamide 1Specimen Handling 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Magnetic Resonance Spectroscopy 1Biopsy 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × Biopsy × 30 days × Clear all
NCT06499870 2026-06-05

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Northwestern University

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡